Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-2: mevrometostat plus enzalutamide versus placebo plus enzalutamide in metastatic castration-resistant prostate cancer
ChiCTR2400093511Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mevrometostat and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by West China Hospital of Sichuan University. Primary endpoint: radiographic progression-free survival. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
mevrometostatenzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ChiCTR2400093511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093511.